Advance Authorization 2026: New Self-Ratification for Pharma Units

## Key points The Directorate General of Foreign Trade (DGFT) has issued **Notification No. 24/2026-27** on August 7, 2026, introducing a streamlined self-ratification scheme specifically for pharmaceutical exporters. Under this update, manufacturers holding a valid 3-year track record and AEO status can now self-certify their input-output norms without waiting for the Norms Committee's prior approval. This significantly reduces the lead time for obtaining an Advance Authorization license for high-value pharma ingredients. ## What this means for exporters This move is a major win for SMEs in the chemical and drug manufacturing sector. By opting for self-ratification, you can import raw materials duty-free immediately based on your technical estimates. This improves cash flow and allows for faster turnaround on international orders. However, post-export audits will be stringent, ensuring that the input-output ratios used are scientifically justifiable. **Who should act now:** Established pharmaceutical manufacturers with AEO T2 status or higher should review their existing norm applications. At **We Design For You**, we specialize in DGFT documentation and Advance Authorization filing. Contact us today to check your eligibility for the self-ratification scheme and ensure your technical data meets the new audit standards.